Dr. Carolyn Baglole received her BSc and MSc from the University of Prince Edward Island, and her PhD from the University of Calgary. She then did postdoctoral research in the fields of lung biology/toxicology in the Department of Environment Medicine at the University of Rochester (Rochester NY) before returning to Canada. She is currently an Associate Professor in the Departments of Pathology, Pharmacology & Therapeutics and Experimental Medicine at McGill University. She is also the Director of the McGill Research Centre for Cannabis, Director of the Histopathology Technology Platform at the Research Institute of the McGill University Health Centre and the Co-Director of the Experimental Pathology Unit at McGill.
Dr. Baglole’s translational research program is designed to identify novel cellular and molecular pathways that control the pathogenesis of chronic lung diseases. Her main research focus is to understand how these environmental exposures contribute to pathogenic mechanisms such as chronic inflammation and cell death (apoptosis) that drive the development of diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer. One of the current focuses in her lab is to understand how various forms of inhaled cannabis and/or cannabinoids affects lung and immune function. Using preclinical models of exposure, her team will investigate activation of cellular signaling pathways by cannabis/cannabinoids, how cannabis affect immune cell numbers and function and whether newer forms of inhaled cannabis impact lung function.